Outlook stock plunges 62% in premarket trading on FDA update

Outlook Therapeutics (NASDAQ:OTLK) stock plunged 62% in premarket trading Thursday after the company said it needed to run an additional clinical trial for its drug ONS-5010 for it to receive FDA approval for the treatment of wet age-related macular degeneration,


Posted

in

by

Tags: